GlassScriptPhysician profile
Norma Perez - Torres
NPI 1023092947
$7,624.02
in general payments reported to CMS, 2019-2025
29 companies · $924 in 2025
The $924 reported for 2025 was more than what 91% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $923 · 2021: $828 · 2022: $1,174 · 2023: $1,545 · 2024: $1,379 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,787 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,786.79 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,708.58 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,194.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $548.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| W. L. Gore & Associates, INC. | $530.53 | 2022-2025 | Gore Acuseal Vascular Graft, Gore Acuseal Cardiovascular Patch Vascular, Gore Propaten Vascular Graft |
| Bayer Healthcare Pharmaceuticals INC. | $454.60 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.72 | 2019-2025 | Jardiance |
| Abbvie INC. | $393.85 | 2019-2024 | |
| Lilly USA, LLC | $375.75 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $359.49 | 2019-2024 | Xarelto |
| Pfizer INC. | $311.57 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $221.39 | 2019-2022 | |
| Astellas Pharma US INC | $214.47 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $194.36 | 2019-2021 | |
| Allergan, INC. | $124.89 | 2019-2020 | |
| Abbott Laboratories | $94.86 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $70.64 | 2025 | Voquezna |
| Amgen INC. | $63.47 | 2019-2024 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $52.24 | 2023-2024 | Gemtesa |
| Eisai INC. | $48.45 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.95 | 2021-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $30.60 | 2022 | |
| Medtronic, INC. | $29.77 | 2025 | Hawkone |
| Exact Sciences Corporation | $28.86 | 2025 | The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $24.18 | 2025 | Korlym |
| Biogen, INC. | $23.38 | 2024 | Spinraza |
| Otsuka America Pharmaceutical, INC. | $18.87 | 2024 | Rexulti |
| Nevro Corp. | $18.43 | 2023 | Senza |
| Alnylam Pharmaceuticals INC. | $16.00 | 2024 | Givlaari |
| Corium, LLC | $14.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Perez - Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.